Soligenix (NASDAQ:SNGX) Stock Passes Above 200 Day Moving Average of $0.00

Shares of Soligenix, Inc. (NASDAQ:SNGX) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.00 and traded as high as $1.15. Soligenix shares last traded at $1.04, with a volume of 1,785 shares.

Several research firms have commented on SNGX. Maxim Group reissued a “buy” rating and issued a $4.00 target price on shares of Soligenix in a research report on Thursday, May 16th. ValuEngine raised shares of Soligenix from a “sell” rating to a “hold” rating in a research report on Thursday, July 18th.

The company has a debt-to-equity ratio of 0.02, a current ratio of 2.20 and a quick ratio of 2.20. The firm has a fifty day simple moving average of $0.95. The stock has a market capitalization of $22.71 million, a price-to-earnings ratio of -1.51 and a beta of 1.16.

Soligenix (NASDAQ:SNGX) last issued its quarterly earnings results on Tuesday, May 14th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.05. Soligenix had a negative net margin of 157.34% and a negative return on equity of 140.01%. The firm had revenue of $1.10 million during the quarter, compared to the consensus estimate of $1.30 million. On average, equities analysts expect that Soligenix, Inc. will post -0.49 EPS for the current fiscal year.

About Soligenix (NASDAQ:SNGX)

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer.

Recommended Story: What is a capital gain?

Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with's FREE daily email newsletter.